ClinicalTrials.gg
TerminatedNCT00755950Updated Apr 23, 2021

Randomized Placebo-controlled Trial Evaluating the Safety and Efficacy of Silymarin Treatment in Patients With Acute Viral Hepatitis

A Phase 2/3 interventional study of Silymarin and Silymarin in Acute Hepatitis A, Acute Hepatitis B and Acute Hepatitis C, sponsored by University of Maryland, Baltimore. Terminated at 3 sites in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-23.

Sponsored by University of Maryland, Baltimore · Phase 2/3, Interventional, and Supportive care

How we know

Why this study was terminated
Low enrollment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess whether two higher doses (280mg or 420mg three times daily)of silymarin therapy are safe and tolerable, and shorten the illness in patients with acute viral hepatitis compared to placebo.

Read the detailed description

Currently, acute viral hepatitis (AVH) management is based on diet and rest and silymarin remains among the most popular herbs being used for treating viral hepatitis both in the U.S. and abroad. Although numerous randomized clinical trials have been conducted to assess the efficacy of silymarin on chronic hepatitis C, very few studies were done to assess the efficacy of silymarin in acute viral hepatitis. Among those, efficacy of silymarin has not been established. This could be attributed to the small number of studies conducted, small sample sizes, high drop out rates, and low doses of silymarin used. Therefore, it is justified to evaluate silymarin safety and efficacy using higher doses than previously studied in AVH.

Primary safety objective:

  • To assess safety and tolerability of two silymarin doses in patients with AVH as determined by the number and percentage of subjects who develop Adverse Events in each group elicited by a questionnaire administered at specific visits and by hematology, blood chemistry and physical examinations.

Primary efficacy objective:

  • To assess the percentage of subjects who normalize their total and direct bilirubin in each group.

Secondary Objective:

To assess the percentage of subjects in each group who:

  • Normalize their liver enzymes, i.e. alanine aminotransferase (ALT), aspartate aminotransferase (AST) and inflammatory reactants, i.e. erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).
  • Resolve their clinical symptoms of AVH and return to baseline activity levels and quality of life (QOL) assessed by physical examinations and using a previously evaluated Arabic-translated SF-36 form adapted for use with patients with liver diseases.

To assess:

  • Differences in silymarin response in different AVH etiologies (i.e. HAV, HBV, HCV, HEV) using subgroup analyses.

To compare:

  • Progression of acute to chronic HCV infection in subjects with HCV-caused acute AVH.
02

Conditions studied

  • Acute Hepatitis A
  • Acute Hepatitis B
  • Acute Hepatitis C
  • Acute Hepatitis E
  • Acute EBV Hepatitis
  • Acute CMV Hepatitis

Browse trials for

Keywords

  • Acute
  • Hepatitis
  • Silymarin
  • Global Health
03

In context

Hepatitis

344 studies on the registry are indexed under Hepatitis; 52 are open to participants now.

This study's enrollment of 70 is below the median of 85 across 245 interventional studies indexed under Hepatitis.

Browse Hepatitis studies →

Lead sponsor

University of Maryland, Baltimore is the lead sponsor of 700 studies on the registry; 131 are open to participants now.

Of its 92 completed or terminated interventional studies of FDA-regulated products, 66 (72%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of acute viral hepatitis (\<1 month) as manifested by a combination of the following symptoms: jaundice, dark-colored urine, light-colored stools, pruritus, pruritic red hives, fever, nausea, vomiting, anorexia, aversion to smoking and right upper abdominal discomfort, pain or feeling of pressure.
  • Serum level > 2.5 times the .
  • Albumin level >3.5 gm/dl
  • Negative anti- antibody
  • Males and females >= 18 years of age.
  • Subject has given written . If patient is between 18 and 21 years parents/legal guardian have/has also signed the informed consent form.
  • The subject is able and willing to undertake all study-required procedures and has the ability to take oral medications.

Exclusion criteria

Exclusion Criteria:

  • Subjects \< 18 years of age
  • Pregnant or breastfeeding women
  • Suspected to silymarin or multivitamins
  • Advanced liver disease (e.g. ascites, bleeding esophageal varices and hepatic encephalopathy)
  • Chronic liver disease as cirrhosis
  • Subjects with positive anti- antibody
  • Simultaneous elevation of > 10 mg/dl along with an level between 100 and 150 U/L
  • count \<150,000
  • Subjects with morbid obesity i.e. a (BMI) > 40
  • Subjects with severe illness, e.g., multisystem failure, cancer or poorly controlled diabetes i.e. known diabetic with (HbA1C)>7%
  • Obvious history of drug-induced acute hepatitis. A careful history of all medications, pesticide and other hepatotoxic exposures occurring within one month prior to symptom onset will be taken. If a patient is unaware of the name of the drugs, (s)he will be asked to bring it for inspection.
  • Current use of Silymarin or recent use within past two weeks.
  • Other conditions, which in the opinion of the investigators, makes the patient unsuitable for enrollment or could interfere with his/her participation in, and completion of, the protocol (e.g. severe mental illness)
  • The subject is currently participating in any clinical trial (marketed product or otherwise), or has done so within 30 days or 5 half-lives (whichever is longer) prior to screening visit
  • History or current drug or alcohol abuse
  • Female patient with without negative pregnancy test
  • Patient is known to be positive.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    1

    280 mg of Silymarin administered three times daily for 4 weeks; Vitamin B complex: B1:thiamine (1.3mg), B2:riboflavin (1.0mg) and B3: nicotinamide (16.5mg)

    Dietary Supplement: Silymarin

  • Placebo comparator
    3

    Placebo: Lactose monohydrate; Vitamin B complex: B1:thiamine (1.3mg), B2:riboflavin (1.0mg) and B3: nicotinamide (16.5mg)

    Other: Lactose monohydrate

  • Experimental
    2.

    420 mg silymarin three times daily for four weeks; Vitamin B complex: B1:thiamine (1.3mg), B2:riboflavin (1.0mg) and B3: nicotinamide (16.5mg)

    Dietary Supplement: Silymarin

Interventions

  • Dietary supplementSilymarin

    280 mg three times daily for four weeks

    Also known as: Legalon, Milk Thistle or St. Mary's Thistle

  • Dietary supplementSilymarin

    420 mg three times daily for four weeks

    Also known as: Legalon, Milk Thistle or St. Mary's Thistle

  • OtherLactose monohydrate

    Lactose monohydrate 326.95 mg three times daily for four weeks

06

What researchers measure

Primary outcomes

  1. Incidence, severity and duration of Adverse Events

    Time frame: Four weeks after enrollment

  2. Normalization of total (<1.0 mg/dl) and direct bilirubin (<0.3 mg/dl)

    Time frame: Four weeks after enrollment

Secondary outcomes

  1. Normalization of ALT, AST, CRP and ESR

    Time frame: Four weeks after enrollment

  2. Symptom resolution & return to normal physical activity

    Time frame: Eight weeks after enrollment

  3. In AVH patients with specific etiologies resolution of clinical signs and symptoms

    Time frame: Eight weeks after enrollment

  4. Persistence of acute HCV with progression to chronicity

    Time frame: Up to 6 months after enrollment

07

Study locations

3 sites
  • Alexandria University Hospital
    Alexandria, Alexandria Governorate, Egypt
  • Tanta Fever Hospital
    Tanta, Gharbeya Governorate, Egypt
  • Banha Fever Hospital
    Benha, Kaluobeya Governorate, Egypt
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2008, a primary completion of Nov 2011 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2008
First posted
Sep 19, 2008
Start
Oct 2008
Primary completionActual
Nov 2011
CompletionActual
Dec 2015
Last update
Apr 23, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00755950
Collaborators
MADAUS GmbH, The Egyptian Company for Blood Transfusion Services, Tanta Fever Hospital, Banha Fever Hospital, Alexandria University
Responsible party
Samer S. El-Kamary (Assistant Professor, University of Maryland, Baltimore) — Principal investigator
First posted
Sep 19, 2008
Start date
Oct 2008
Primary completion
Nov 2011
Completion
Dec 2015
Last update
Apr 23, 2021

Study contacts

Samer El-Kamary, MD, MPH
principal investigator · University of Maryland, College Park
George T Strickland, MD, PhD,
study chair · University of Maryland, College Park
Mohamed Hashem, MD
study director · University of Maryland, College Park

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Silymarin

Start the discussion